

表26. 抗体価の変化: B(0.25mL)

| ワクチン種別 | 接種後 | 接種前抗体価 | | | | | | | | | | 計 | | | |
|--------|--------|--------|-----|----|----|----|-----|-----|-----|--------|--|---|--|-----|-----|
| | | 10未満 | 10 | 20 | 40 | 80 | 160 | 320 | 640 | 1280以上 | | | | | |
| ビケン | 1280以上 | | | | | | | | | | | | | | |
| | 640 | | | | | | | | | | | | | | |
| | 320 | 3 | | 1 | | | | | | | | | | 4 | |
| | 160 | 2 | | | | | | | | | | | | 2 | |
| | 80 | 1 | | | | | | | | | | | | 1 | |
| | 40 | 14 | | 1 | | | | | | | | | | 15 | |
| | 20 | 17 | | | | | | | | | | | | 17 | |
| | 10 | 33 | | | | | | | | | | | | 33 | |
| | 10未満 | 54 | | | | | | | | | | | | 54 | |
| | ビケン計 | | 124 | | 2 | | | | | | | | | | 126 |
| サノファイ | 1280以上 | | | | | | | | | | | | | | |
| | 640 | | | | | | | | | | | | | | |
| | 320 | 1 | | | | | | | | | | | | 1 | |
| | 160 | 2 | | | | | | | | | | | | 2 | |
| | 80 | 4 | 2 | | 1 | | | | | | | | | 7 | |
| | 40 | 4 | | | | | | | | | | | | 4 | |
| | 20 | 16 | 1 | | | | | | | | | | | 17 | |
| | 10 | 39 | | | | | | | | | | | | 39 | |
| | 10未満 | 55 | | | | | | | | | | | | 55 | |
| | サノファイ計 | | 121 | 3 | | 1 | | | | | | | | | 125 |
| 総計 | | 245 | 3 | 2 | 1 | | | | | | | | | 251 | |

阪大ビケン1回目平均抗体価 × 5.1 阪大ビケン2回目平均抗体価 × 11.4
 サノファイ1回目平均抗体価 × 5.2 サノファイ2回目平均抗体価 × 10.2

表27. 抗体価の変化: B(0.50mL)

| ワクチン種別 | 接種後 | 接種前抗体価 | | | | | | | | | | 計 | | | |
|--------|--------|--------|----|----|----|----|-----|-----|-----|--------|--|---|--|-----|-----|
| | | 10未満 | 10 | 20 | 40 | 80 | 160 | 320 | 640 | 1280以上 | | | | | |
| ビケン | 1280以上 | | | | | | | | | | | | | | |
| | 640 | | | | | | | | | | | | | | |
| | 320 | | | 1 | | | | | | | | | | | 1 |
| | 160 | 1 | | | 2 | | | | | | | | | | 3 |
| | 80 | 3 | 5 | 2 | 4 | | | | | | | | | | 14 |
| | 40 | 5 | 8 | 12 | 5 | | | | | | | | | | 30 |
| | 20 | 14 | 11 | 1 | | | | | | | | | | | 26 |
| | 10 | 25 | 7 | | | | | | | | | | | | 32 |
| | 10未満 | 48 | 1 | | | | | | | | | | | | 49 |
| | ビケン計 | 96 | 32 | 16 | 11 | | | | | | | | | | 155 |
| サノファイ | 1280以上 | | | | | | | | | | | | | | |
| | 640 | | | | | | | | | | | | | | |
| | 320 | 1 | | | | | | | | | | | | | 1 |
| | 160 | | 1 | | | 1 | | | | | | | | | 2 |
| | 80 | 1 | 3 | 1 | 3 | 3 | | | | | | | | | 11 |
| | 40 | 5 | 6 | 9 | 4 | 3 | | | | | | | | | 24 |
| | 20 | 6 | 15 | 1 | | | | | | | | | | | 22 |
| | 10 | 33 | 13 | | | | | | | | | | | | 46 |
| | 10未満 | 39 | | | | | | | | | | | | | 39 |
| | サノファイ計 | 85 | 38 | 11 | 7 | 4 | | | | | | | | | 145 |
| 総計 | 181 | 70 | 27 | 18 | 4 | | | | | | | | | 300 | |

阪大ビケン1回目平均抗体価 × 7.7 阪大ビケン2回目平均抗体価 × 15.4

サノファイ1回目平均抗体価 × 7.9 サノファイ2回目平均抗体価 × 14.4

表28. 抗体価幾何平均の変化

| 接種量 | ワクチン種別 | AH1平均抗体価 | | | AH3平均抗体価 | | | B平均抗体価 | | |
|------------------|--------|----------|------|------|----------|------|-------|--------|-----|------|
| | | 対象者* | 接種前 | 2回後 | 対象者 | 接種前 | 2回後 | 対象者 | 接種前 | 2回後 |
| 0.25mL (3歳未満) | ビケン | 107 | 6.0 | 40.8 | 126 | 7.6 | 17.1 | 126 | 5.1 | 11.4 |
| | サノファイ | 111 | 6.1 | 82.0 | 125 | 11.1 | 93.4 | 125 | 5.2 | 10.2 |
| 0.50mL (3歳以上) | ビケン | 140 | 11.4 | 79.6 | 155 | 19.4 | 36.4 | 155 | 7.7 | 15.4 |
| | サノファイ | 136 | 13.3 | 69.0 | 145 | 74.1 | 175.4 | 145 | 7.9 | 14.4 |
| 0.25mL (2歳) | ビケン | 45 | 6.7 | 43.9 | 48 | 8.3 | 22.8 | 48 | 5.1 | 14.6 |
| | サノファイ | 44 | 6.9 | 55.7 | 49 | 18.4 | 85.9 | 49 | 5.4 | 11.4 |
| 0.50mL (3歳) | ビケン | 20 | 6.8 | 49.2 | 23 | 13.5 | 26.2 | 23 | 5.5 | 11.6 |
| | サノファイ | 20 | 6.8 | 42.9 | 20 | 26.4 | 117.1 | 20 | 5.2 | 10.0 |

* AH1亜型については、平成19年50週までに2回目のワクチン接種済み者で制限

表29. 40倍以上の抗体価獲得率

| 接種量 | ワクチン種別 | 2回接種後AH1抗体価 | | 2回接種後AH3抗体価 | | 2回接種後B抗体価 | | | | |
|------------------|--------|----------------|-----|---------------|-----|---------------|------|-----|----|------|
| | | 対象者* 40倍以上 (%) | (%) | 対象者 40倍以上 (%) | (%) | 対象者 40倍以上 (%) | (%) | | | |
| 0.25mL (3歳未満) | ビケン | 101 | 60 | 59.4 | 108 | 22 | 20.4 | 124 | 20 | 16.1 |
| | サノファイ | 106 | 82 | 77.4 | 99 | 76 | 76.8 | 124 | 13 | 10.5 |
| 0.50mL (3歳以上) | ビケン | 96 | 64 | 66.7 | 63 | 14 | 22.2 | 128 | 22 | 17.2 |
| | サノファイ | 91 | 62 | 68.1 | 26 | 13 | 50.0 | 122 | 17 | 13.9 |
| 0.25mL (2歳) | ビケン | 40 | 22 | 55.0 | 38 | 13 | 34.2 | 47 | 12 | 25.5 |
| | サノファイ | 41 | 26 | 63.4 | 32 | 20 | 62.5 | 48 | 6 | 12.5 |
| 0.50mL (3歳) | ビケン | 17 | 10 | 58.8 | 14 | 3 | 21.4 | 23 | 5 | 21.7 |
| | サノファイ | 19 | 13 | 68.4 | 9 | 5 | 55.6 | 20 | 3 | 15.0 |

ワクチン接種前の抗体価10倍以下で制限

* AH1亜型については、平成19年50週までに2回目のワクチン接種済み者で制限

表30. 単変量(χ^2 検定)及び多変量(多重ロジスティックモデル)解析による因子分析:2回接種後40倍以上の抗体保有(AH1)

| 質的説明変数 | カテゴリ | 発生 / 対象者数 * | χ^2 検定 | | 多重ロジスティックモデル | |
|--------------|--------------|-------------|------------------|-------|------------------|---------------------------|
| | | | RR ^{※1} | p値 | OR ^{※2} | (95% CI) p値 |
| ①ワクチン | ビケン | 122 / 195 | 1 | | 1 | |
| | サノファイ | 138 / 190 | 1.16 | 0.045 | 1.72 | (1.09 - 2.70) 0.019 * |
| ②性別 | 男 | 140 / 212 | 1 | | 1 | |
| | 女 | 120 / 173 | 1.05 | 0.559 | 1.23 | (0.78 - 1.93) 0.375 |
| ③過去3年間の予防接種歴 | なし | 107 / 134 | 1 | | 1 | |
| | あり | 153 / 251 | 0.76 | 0.000 | 0.25 | (0.14 - 0.45) 0.000 *** |
| ④昨冬A型罹患 | なし | 238 / 358 | 1 | | 1 | |
| | あり | 22 / 27 | 1.23 | 0.164 | 2.93 | (1.03 - 8.34) 0.044 * |
| ⑤昨冬B型罹患 | なし | 248 / 368 | 1 | | 1 | |
| | あり | 12 / 17 | 1.05 | 0.992 | 0.87 | (0.28 - 2.65) 0.801 |
| ⑥接種量(年齢) | 0.25mL(3歳未満) | 138 / 203 | 1 | | 1 | |
| | 0.50mL(3歳以上) | 122 / 182 | 0.99 | 0.929 | 2.12 | (1.23 - 3.67) 0.007 ** |
| ⑦喘息又はアトピー | なし | 238 / 341 | 1 | | 1 | |
| | あり | 22 / 44 | 0.72 | 0.014 | 0.44 | (0.23 - 0.86) 0.016 * |

※1:RRはリスク比(発生率の比)

※2:ORは多重ロジスティックモデルによる調整オッズ比

分析対象者 385名 : 前記10名+①~⑩に欠落があるケースを分析から除外、接種前の抗体価10倍以下で制限
平成19年50週以前に2回のワクチン接種が完了している者に制限

表31. ワクチン2回接種後の抗体価別インフルエンザ罹患時の最高発熱

| 罹患時の最高発熱 | ワクチン2回接種後のAH1抗体価 | | | | | | | | | | 患者数 | |
|----------|------------------|-----|-----|-----|----|----|----|----|------|---|-----|----|
| | 1280以上 | 640 | 320 | 160 | 80 | 40 | 20 | 10 | 10未満 | | | |
| ～37.9℃ | | | | | 1 | | | | | | | 1 |
| ～38.4℃ | | | | | | | 2 | 1 | | | | 3 |
| ～38.9℃ | | | 1 | 4 | | | 3 | | | 2 | | 14 |
| ～39.4℃ | | | 1 | | 2 | 4 | 1 | 2 | 3 | | | 13 |
| ～39.9℃ | | | | | 1 | 1 | 1 | 4 | | | | 7 |
| 40℃～ | | | | | | | 1 | | 1 | | | 2 |
| 計 | | | 2 | 4 | 4 | 4 | 8 | 7 | 6 | | | 40 |

□内は40倍以上の抗体価があるにも関わらず、38.5℃以上の発熱を来した患者対象者は、平成19年50週以前に2回のワクチン接種が完了している者に制限

| 発生時期 | 51W | 52W | 01W | 02W | 03W | 04W | 05W | 06W | 07W | 08W | 09W | 10W | 計 |
|----------|-----|-----|-----|------|------|------|------|------|-----|-----|-----|-----|----|
| 調査対象患者数 | 1 | 0 | 0 | 4 | 3 | 11 | 13 | 11 | 1 | 2 | 0 | 1 | 47 |
| 定点あたり患者数 | 3.5 | 6.2 | 4.5 | 10.2 | 22.6 | 42.8 | 41.7 | 23.5 | 10 | 7.8 | 5.7 | 3.2 | |

2007/2008シーズン 患者発生状況




図1. 2007/2008シーズン 患者発生状況

研究成果の刊行に関する一覧表

| 発表者氏名 | 論文タイトル名 | 発表誌名 | 巻号 | 頁 | 出版年 |
|--|--|------------------|-----|-----------|------|
| Masaki Imai, Kazunori Kawasaki, and Takato Odagiri | Cytoplasmic domain of influenza B virus BM2 protein plays critical roles in production of infectious virus | J. Virol. | 82 | 728-739 | 2008 |
| H Kamijuku, Y Nagata, X Jiang, T Ichinohe, T Tashiro, K Mori, M Taniguchi, K Hase, H Ohno, T Shimaoka, S Yonehara, T Odagiri, M Tashiro, T Sata, H Hasegawa and K-i Seino. | Mechanism of NKT cell activation by intranasal coadministration of alfa-galactosylceramide, which can induce cross-protection against influenza viruses | Mucosal Immunol. | 1 | 208-218 | 2008 |
| Russell CA, Jones TC, Barr IG, Cox NJ, Garten RJ, Gregory V, Gust ID, Hampson AW, Hay AJ, Hurt AC, de Jong JC, Kelso A, Klimov AI, Kageyama T, Komadina N, Lapedes AS, Lin YP, Mosterin A, Obuchi M, Odagiri T, Osterhaus AD, Rimmelzwaan GF, Shaw MW, Skepner E, Stohr K, Tashiro M, Fouchier RA, Smith DJ. | The global circulation of seasonal influenza A (H3N2) viruses | Science. | 320 | 340-6 | 2008 |
| Keiichi Makizumi, Kazuhiko Kimachi, Katsuhiko Fukada, Tomohiro Nishimura, Yasuhiro Kudo, Shuro Goto, Takato Odagiri, Masato Tashiro, Yoichiro Kino | Timely production of A/Fujian-like influenza vaccine matching the 2003–2004 epidemic strain may have been possible using Madin–Darby canine kidney cells | Vaccine | 26 | 6852-6858 | 2008 |
| Kamijuku H., Nagata, Y., Ichnose, T., Jiang X., Tashiro, T., Mori, K., Taniguchi, Y., Hase, K., Ohno, H., Shimaoka, T., Tonehara, S., Odagiri, T., Tashiro, M., Sata, T., Hasegawa, H., Seino, K. | Mechanism of NKT cell activation by intranasal coadministration of galactosylceramide which can induce cross-protection against influenza viruses. | Mucosal Immunol | 1 | 208-218 | 2008 |
| Ogata, T., Yamazaki, Y., Okabe, N., Nakamura, Y., Tashiro, M., Nagata, N., Itamura, S., Yasui, Y., Nakashima, K., Doi, M., Izumi, Y., Fujieda, T., Yamato, S., Kawada, Y | H5N2 influenza infection to human in Japan and association of seasonal influenza vaccination with positive H5N2 neutralizing antibody | J. Epidemiol. | 18 | 160-166 | 2008 |
| Kubota, T., Matuoka, M., Chang, | Virus infection triggers SUMOylation of | J. Biol. | 283 | 25660 | 2008 |

| | | | | | |
|--|--|----------------------|----|---------------|----------|
| T.-H., Taylor, P., Sasaki, T., Tashiro, M., Kato, A., Ozato, K. | IRF3 and IRF7, leading to the negative regulation of type I interferon gene expression. | Chem. | | -2567 0 | |
| Russell, C. A., Jones, T. C., Barr, I. G., Cox, N. J., Gregory, V., Gust, I. D., Hampson, A. W., Hay, A. J., Hurt, A. C., de Jong, J. C., Kelso, A., Klimov, A. I., Kageyama, T., Komadina, N., Lapedes, A. S., Lin, Y. P., Mosterin, A., Obuchi, M., Odagiri, T., Osterhaus, A. D.M.E., Rimmelzwaan, G. F., Shaw, M. W., Skepner, E., Stohr, K., Tashiro, M., Fouchier, R. A.M., Smith, D. J. | Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses | Vaccine | 26 | 31-34 | 2008 |
| Makizumi, K., Kimachi, K., Fukada, K., Nishimura, T., Kudo Y., Goto, S., Odagiri, T., Tashiro, M., Kino, Y. | Timely production of A/Fujian-like influenza vaccine matching the 2003–2004 epidemic strain may have been possible using Madin–Darby canine kidney cells | Vaccine | 26 | 6852- 6858 | 2008 |
| Kawakami, C., Obuchi, M., Saikusa, M., Noguchi, Y., Ujike, M., Odagiri, T., Tashiro, M. | Outbreaks of oseltamivir-resistant influenza A/H1N1 virus in an elementary school and a family in Yokohama City, Japan during the 2007-2008 season. | Jpn. J. Infect. Dis. | 62 | 83-86 | 2008 |
| Takahashi, Y., Hasegawa, H., Hara, Y., Ato, N., Ninomiya, A., Takagi, H., Odagiri, T., Sata, T., Tashiro, M., Kobayashi, M. | Protective immunity afforded by H5N1 (NIBRG-14) - inactivated vaccine requires both antibodies against hemagglutinin and neuraminidase in mice. | J. Infect. Dis. | | | In press |
| Wada, T., Morishima, T., Okumura, A., Tashiro, M., Hosoya, M., Shiomi, M., Okuno, Y. | Differences by age in clinical manifestations of influenza-associated encephalopathy. | Microbiol. Immunol. | | | In press |
| Ikeno, D., Kimachi, K., Kudo, Y., Goto, S., Itamura, S., Odagiri, T., Tashiro, M., Kino, Y. | The prime-boost vaccination of H5N1 heterologous strains in a mouse model | Vaccine | | | In press |
| Murakami S, Horimoto T, Mai le Q, Nidom CA, Chen H, Muramoto Y, Yamada S, Iwasa A, Iwatsuki-Horimoto K, Shimojima M, Iwata A, Kawaoka Y. | Growth determinants for H5N1 influenza vaccine seed viruses in MDCK cells. | J Virol. | 82 | 10502 -9 | 2008 |

| | | | | | |
|--|--|--|-----|-----------|----------|
| Takahashi, Y., Hasegawa, H., Hara, Y., Ato, M., Ninomiya, A., Takagi, H., Odagiri, T., Sata, T., Tashiro, M., Kobayashi, K. | Protective immunity afforded by H5N1 (NIBRG-14)-inactivated vaccine requires both antibodies against hemagglutinin and neuraminidase in mice. | J. Infect. Dis. | | | In press |
| Nagata N, Iwata N, Hasegawa H, Fukushi S, Harashima A, Sato Y, Saijo M, Taguchi F, Morikawa S, Sata T. | Mouse-passaged severe acute respiratory syndrome-associated coronavirus leads to lethal pulmonary edema and diffuse alveolar damage in adult but not young mice. | Am J Pathol. | 172 | 1625-37. | 2008 |
| Kamijuku H, Nagata Y, Jiang X, Ichinohe T, Tashiro T, Mori K, Taniguchi M, Hase K, Ohno H, Shimaoka T, Yonehara S, Odagiri T, Tashiro M, Sata T, Hasegawa H, Seino KI. | Mechanism of NKT cell activation by intranasal coadministration of alpha-galactosylceramide, which can induce cross-protection against influenza viruses | Mucosal Immunol | 3 | 208-18 | 2008 |
| Ichinohe T, Iwasaki A, Hasegawa H | Innate sensors of influenza virus: clues to developing better intranasal vaccines. | Expert Rev Vaccines. | 7 | 1435-45 | 2008 |
| Hasegawa H, Ichinohe T, Ainai A, Tamura S, Kurata T. | Development of an inactivated mucosal vaccine for H5N1 influenza virus. | Therapeutic and Clinical Risk Management | | | In press |
| Takahashi Y, Hasegawa H, Hara Y, Ato M, Ninomiya | Protective immunity afforded by H5N1 (NIBRG-14)-inactivated vaccine requires both antibodies against hemagglutinin and neuraminidase in mice. | J Infect Dis | | | in press |
| 神谷 齊 | 臨床の立場からみたワクチンの重要性. | ファルマシア | 44 | 23-27 | 2008 |
| 神谷 齊、岩田 敏、石和田 稔彦、山中 昇、杉田麟也 | 小児用7価肺炎球菌結合型ワクチンの医療経済効果 | 小児科臨床. | 61 | 2233-2241 | 2008 |